Lymphatic Metastasis Predicts Better Response to Nivolumab in Recurrent or Metastatic Gastric Cancer: Insights from Tumor-Draining Lymph Node Immunity and Long-Term Outcomes
The pattern of metastatic spread, particularly lymphatic involvement, appears to influence the efficacy of nivolumab in advanced or recurrent gastric cancer. Recognizing metastatic patterns may assist in optimizing patient selection and therapeutic strategies for immune checkpoint blockade.
Authors
- Yasuyoshi Sato (ORCID: https://orcid.org/0000-0003-4145-8694)
- Raito Asaoka
- Yasuyuki Seto (ORCID: https://orcid.org/0000-0002-6953-8752)
- Shuichiro Oya (ORCID: https://orcid.org/0000-0002-7532-4072)
- Kotaro Sugawara (ORCID: https://orcid.org/0000-0002-3272-1748)
- Shoh Yajima (ORCID: https://orcid.org/0000-0001-8838-6283)
- Hiroharu Yamashita (ORCID: https://orcid.org/0000-0002-9468-3716)
- Koichi Yagi (ORCID: https://orcid.org/0000-0001-8319-8005)
- Yoshifumi Baba
- Yoshiyuki Miwa
- Asami Okamoto
Institutions
- Jichi Medical University (JP)
- Bunkyo University (JP)
- National Cancer Centre Japan (JP)
- University of Tokyo Hospital (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Oncology
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1159/000549852
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00